Lamin A is formed from prelamin A by four post-translational processing steps-farnesylation, release of the last three amino acids of the protein, methylation of the farnesylcysteine and the endoproteolytic release of the C-terminal 15 amino acids (including the farnesylcysteine methyl ester). When the final processing step does not occur, a farnesylated and methylated prelamin A accumulates in cells, causing a severe progeroid disease, restrictive dermopathy (RD). Whether RD is caused by the retention of farnesyl lipid on prelamin A, or by the retention of the last 15 amino acids of the protein, is unknown. To address this issue, we created knock-in mice harboring a mutant Lmna allele (Lmna nPLAO ) that yields exclusively non-farnesylated prelamin A (and no lamin C). These mice had no evidence of progeria but succumbed to cardiomyopathy. We suspected that the non-farnesylated prelamin A in the tissues of these mice would be strikingly mislocalized to the nucleoplasm, but this was not the case; most was at the nuclear rim (indistinguishable from the lamin A in wild-type mice). The cardiomyopathy could not be ascribed to an absence of lamin C because mice expressing an otherwise identical knock-in allele yielding only wild-type prelamin A appeared normal. We conclude that lamin C synthesis is dispensable in mice and that the failure to convert prelamin A to mature lamin A causes cardiomyopathy (at least in the absence of lamin C). The latter finding is potentially relevant to the long-term use of protein farnesyltransferase inhibitors, which lead to an accumulation of nonfarnesylated prelamin A.
INTRODUCTION
Lamin A, a key component of the nuclear lamina, is formed from a precursor protein, prelamin A, by four enzymatic posttranslational processing steps-farnesylation of a cysteine located four amino acids from the C terminus of the protein, endoproteolytic cleavage of the last three amino acids of the protein, carboxyl methylation of the newly exposed farnesylcysteine and endoproteolytic release of the last 15 amino acids of the protein (including the farnesylcysteine methyl ester) (1 -5) . The last endoproteolytic cleavage step, which releases mature lamin A, is carried out by ZMPSTE24, a membrane zinc metalloproteinase of the endoplasmic reticulum (6 -9) .
Defects in prelamin A processing and lamin A biogenesis have been linked to progeroid disorders in humans. The classic pediatric progeroid disease, the Hutchinson -Gilford progeria syndrome (HGPS), is caused by a LMNA point mutation that alters mRNA splicing, resulting in a 50 amino acid internal deletion in prelamin A (10) . This deletion does not affect the C-terminal farnesylation or methylation, but it does remove the site for the last ZMPSTE24 cleavage event.
The elimination of the final processing step causes an accumulation of a truncated prelamin A, commonly called progerin, *
To whom correspondence should be addressed at: 695 Charles Young Dr South, Los Angeles, CA 90095, USA. Tel: +1 3102674380; Fax: +1 3102672722; Email: lfong@mednet.ucla.edu that retains a C-terminal farnesylcysteine methyl ester (11, 12) . Aside from the farnesylcysteine methyl ester, progerin contains four additional C-terminal residues that are not found in mature lamin A.
Progerin adversely affects the integrity and function of the nuclear lamina, leading to misshapen nuclei in cultured cells and a host of aging-like disease phenotypes (10, 13) . The frequency of misshapen nuclei in HGPS fibroblasts is reduced with a protein farnesyltransferase inhibitor (FTI) (14) (15) (16) (17) (18) . Recently, Yang et al. (19) generated knock-in mice expressing farnesylated progerin (Lmna HG/+ ) and tested whether their progeria-like disease phenotypes might be ameliorated by an FTI. In three independent studies, FTI treatment lessened the severity of disease phenotypes in Lmna HG/+ mice (19) (20) (21) . These mouse experiments prompted a clinical trial of FTI therapy in children with HGPS (22) .
The favorable results with FTI therapy in Lmna HG/+ mice have raised hopes for a positive outcome of the FTI trial in humans. However, recent genetic studies in mice have suggested that the FTI treatment strategy may be destined to fall short of a complete cure. Yang et al. (12) generated knock-in mice expressing a 'non-farnesylated' version of progerin (Lmna nHG/+ ) and showed that those animals developed severe progeria (although somewhat less severe than in mice producing farnesylated progerin). The finding that nonfarnesylated progerin elicits disease suggested that an altered primary structure (i.e. the 50 amino acid deletion)-and not merely the farnesyl lipid-contributes to the pathogenesis of HGPS.
A more severe progeroid syndrome, restrictive dermopathy (RD), is caused by a deficiency in ZMPSTE24. ZMPSTE24 deficiency abolishes the final processing step that releases mature lamin A, resulting in an accumulation of a farnesylated and methylated prelamin A. Unlike HGPS, the prelamin A in RD does not have an internal deletion. It does, however, retain the extra 15 amino acids at its C terminus-the segment that is normally absent in mature lamin A.
Currently, no one understands why the accumulation of prelamin A in RD patients (and ZMPSTE24-deficient mice) elicits a progeroid syndrome. One possibility is that disease is largely due to the retention of the farnesyl lipid at the C terminus of prelamin A. However, there are other possibilities. For example, one could reasonably speculate that the extra 15 amino acids at prelamin A's C terminus-and not the lipid anchor-elicit disease. The proposition that an altered primary structure of prelamin A might elicit progeria is not farfetched, given that non-farnesylated progerin causes progeria in mice (12) and given that certain missense mutations in lamins A/C cause progeria in humans (10, 23) .
In the current study, we tested the hypothesis that the retention of the last 15 amino acids of prelamin A is sufficient to elicit progeria in mice. To approach this issue, we created and analyzed Lmna knock-in mice that produce exclusively non-farnesylated prelamin A.
RESULTS
We created Lmna knock-in mice expressing exclusively nonfarnesylated prelamin A or exclusively wild-type prelamin A.
To create a mutant allele yielding only non-farnesylated prelamin A ('non-farnesylated prelamin A-only' allele, Lmna nPLAO ), we used gene targeting to remove introns 10 and 11 (thereby abolishing lamin C synthesis) and to change the cysteine in the CaaX motif to a serine (abolishing protein prenylation; Fig. 1A ). To create an allele yielding only wild-type prelamin A ('prelamin A-only' allele, Lmna PLAO ), we used the same gene-targeting vector except that the cysteine within the CaaX motif was not altered (Fig. 1B) . Targeted embryonic stem (ES) cell clones (Fig. 1C) were used to create chimeric mice, which were bred to produce heterozygous mice (Lmna nPLAO/+ and Lmna PLAO/+ ). Heterozygotes were then intercrossed to produce homozygotes. Lmna nPLAO/+ embryonic fibroblasts produced lamin A, lamin C and prelamin A, whereas Lmna nPLAO/nPLAO fibroblasts produced exclusively prelamin A (Fig. 1D) . Extracts of Lmna PLAO/PLAO embryonic fibroblasts contained only mature lamin A (produced from the processing of prelamin A; Fig. 1E ). Western blots of extracts from the hearts of Lmna nPLAO/nPLAO and Lmna PLAO/PLAO mice yielded the expected lamin proteins in the expected amounts (Fig. 1F) .
Treatment of fibroblasts with an FTI prevents farnesylation of prelamin A and thus prevents the multistep pathway that converts prelamin A to mature lamin A (12, 18) . When Lmna +/+ and Lmna PLAO/PLAO fibroblasts were incubated with an FTI, nonfarnesylated prelamin A accumulated and was easily detectable by western blotting (i.e. the lamin protein that migrates above mature lamin A; Fig. 2A ). The FTI did not affect the migration of the non-farnesylated prelamin A in Lmna nPLAO/nPLAO fibroblasts ( Fig. 2A) . To verify that the prelamin A in Lmna nPLAO/nPLAO fibroblasts was not farnesylated, we incubated Lmna nPLAO/nPLAO and Zmpste24 2/2 fibroblasts with a farnesol analog, 8-anilinogeraniol (AG) (24) . After entering cells, AG is incorporated into anilinogeranyl diphosphate (AGPP), which is used as a substrate by protein farnesyltransferase (FTase) for modifying CaaX proteins, including prelamin A. The prelamin A in Zmpste24 2/2 fibroblasts was labeled with AG, and this labeling was largely eliminated with an FTI (Fig. 2B ). As expected, there was no AG labeling of the prelamin A in Lmna nPLAO/nPLAO fibroblasts, with or without an FTI (Fig. 2B ). In wild-type mouse fibroblasts, lamin A was present at the nuclear rim, but significant amounts were also found in the nucleoplasm (Fig. 3A) . Similarly, in Lmna PLAO/PLAO fibroblasts, most of lamin A was located at the nuclear rim (Fig. 3A) . In Lmna nPLAO/nPLAO fibroblasts, some of the prelamin A was at the rim, but substantial amounts were located in the nucleoplasm (Fig. 3A) . Also, a higher percentage of the nuclei of Lmna nPLAO/nPLAO fibroblasts was misshapen, with blebs and folds (P , 0.0001; Fig. 3B and C) . Although the nuclei of Lmna nPLAO/nPLAO fibroblasts were misshapen, the stiffness of Lmna nPLAO/nPLAO nuclei was not significantly different than nuclei of wild-type fibroblasts ( Fig. 3D and E) .
Immunofluorescence microscopy of tissues from wild-type, Lmna PLAO/PLAO and Lmna nPLAO/nPLAO mice did not uncover differences in the patterns of lamin A/prelamin A localization. In wild-type and Lmna PLAO/PLAO tissues, virtually all the lamin A was at the nuclear rim (Fig. 4) . Similarly, virtually all the prelamin A in Lmna nPLAO/nPLAO tissues was located at the nuclear rim (Fig. 4) .
Body weight curves in male Lmna +/+ , Lmna PLAO/PLAO and Lmna nPLAO/nPLAO mice were not significantly different (Fig. 5A ), but female Lmna PLAO/PLAO and Lmna nPLAO/nPLAO mice appeared to have slightly lower body weights than Lmna +/+ littermates (Fig. 5B) . The survival of Lmna PLAO/PLAO mice was not different than that of wild-type mice. Male and female Lmna nPLAO/nPLAO mice appeared to be entirely normal for the first 20 weeks of life. After that, however, we observed premature death in males and females; all male Lmna nPLAO/nPLAO mice succumbed by 44 weeks of age (median survival, 38.5 weeks) and all female mice succumbed by 80 weeks (median survival, 49.5 weeks). Kaplan-Meier survival analysis revealed that the survival of Lmna nPLAO/nPLAO mice was significantly reduced, compared with Lmna +/+ or 
Lmna
PLAO/PLAO mice (P , 0.0001 for both males and females; Fig. 5C and D).
The premature death in Lmna nPLAO/nPLAO mice suggested that non-farnesylated prelamin A might elicit cardiomyopathy. Indeed, echocardiography revealed that Lmna nPLAO/nPLAO mice had a dilated cardiomyopathy ( Fig. 6A and B) , with an increased left ventricular (LV) chamber size during systole ( Fig. 6C ) and a reduced LV ejection fraction (Fig. 6D ). In keeping with these findings, the expression of myosin heavy chain alpha (Myh6), which typically falls in the setting of cardiomyopathy (25) , was reduced in Lmna nPLAO/nPLAO mice (Fig. 6E ). The expression of myosin heavy chain beta (Myh7), a marker of cardiomyopathy (25) , was increased in Lmna nPLAO/nPLAO mice (Fig. 6F ). This cardiomyopathy phenotype, with a greater severity in males, is similar to the phenotype of Lmna knock-in mice carrying an H222P substitution (26) . Lmna H222P/H222P mice were reported to have a 'marked increase in fibrosis' in the left and right ventricles. We examined cardiac pathology in an Lmna nPLAO/nPLAO mouse that had severe cardiomyopathy by echocardiography and found significant fibrosis in the papillary muscle of the left ventricle, as judged by a Gomori trichrome stain (Fig. 7) . No such fibrosis was observed in the papillary muscle of an age-matched Lmna +/+ control mouse (Fig. 7) . We would characterize the fibrosis in the Lmna nPLAO/nPLAO mouse as being mild -moderate, and in some mice, fibrosis was minimal.
In humans, lamin-related progeroid syndromes are associated with osteolytic lesions in bones, a severe growth defect, and reduced survival (10, 27, 28) . Zmpste24 2/2 mice share these phenotypes. Indeed, osteolytic lesions and spontaneous rib fractures are prominent in Zmpste24 2/2 mice, which accumulate the farnesylated form of prelamin A (Fig. 8) . Interestingly, Lmna nPLAO/nPLAO mice did not have osteolytic lesions in any of their bones, and rib fractures were never observed ( Fig. 8 ). Bone lesions were also absent in Lmna PLAO/PLAO mice ( Fig. 8 ). Zmpste24 2/2 and Lmna nPLAO/nPLAO mice also differed in their body weight curves. Zmpste24 2/2 mice were far smaller than wild-type mice, and they invariably die from severe, progressive inanition (6, 8, 9 ; also see Fig. 9 ). At 5 -6 months of age, Zmpste24 2/2 mice typically weigh only 11-17 g (6,8,9; also see Fig. 9 ), whereas 5 -6-month-old Lmna nPLAO/nPLAO typically weigh 30-40 g (Fig. 5) . Thus, the non-farnesylated prelamin A in Lmna nPLAO/nPLAO mice elicits none of the progeria-like disease phenotypes found in Zmpste24 2/2 mice, but it does cause cardiomyopathy.
The Lmna PLAO allele yields exclusively prelamin A, whereas a wild-type Lmna allele yields both lamin C and prelamin A. Because all of the output of the Lmna PLAO allele is channeled into prelamin A production, we predicted that the Lmna PLAO allele would increase prelamin A levels in Zmpste24 2/2 mice and worsen disease phenotypes. Indeed, this was the case. Prelamin A levels increased with each additional Lmna PLAO allele ( Fig. 9A and B) , and both body weight and survival worsened ( Fig. 9C and D) .
DISCUSSION
Finding progeria-like disease phenotypes in 'non-farnesylated progerin mice' (12) was intriguing because it suggested that the primary structure of progerin, and not merely its farnesyl lipid anchor, could be central to the pathogenesis of HGPS. Those findings immediately raised parallel questions about the pathogenesis of RD (ZMPSTE24 deficiency). When ZMPSTE24 is absent, are the disease phenotypes elicited by the retention of the hydrophobic lipid anchor on prelamin A or are they due to the extra 15 amino acids at the protein's C terminus? To address this issue, we created 'knock-in mice' (Lmna nPLAO/nPLAO ) that synthesize exclusively nonfarnesylated prelamin A. Given the unequivocal findings with 'non-farnesylated progerin mice', we hypothesized that , Lmna nPLAO/nPLAO and Zmpste24 2/2 fibroblasts in the presence and the absence of an FTI (ABT-100; 5 mM). Actin was used as a loading control. (B) Metabolic labeling experiment with a farnesol analog, AG to assess the farnesylation of prelamin A. Fibroblasts were incubated with AG (50 mM) in the presence (+) or the absence (2) of an FTI (ABT-100, 5 mM). Western blots were performed on cell extracts with an antibody specific for lamin A/ C (green) and an antibody specific for AG (red). As expected, the FTI blocked the incorporation of AG into the prelamin A in Zmpste24 2/2 fibroblasts. No farnesylation of prelamin A in Lmna nPLAO/nPLAO cells was detected. In the AG western blot, lamin B1 was detected (electrophoretic mobility intermediate between lamin A and lamin C); this band disappeared with an FTI. A non-specific band was also observed in the AG western blot (electrophoretic band immediately beneath lamin C).
the 'non-farnesylated prelamin A mice' would manifest all the same progeria-like disease phenotypes found in Zmpste24 2/2 mice. To our surprise, this hypothesis was proven wrong. Even though Lmna nPLAO/nPLAO mice expressed very high levels of non-farnesylated prelamin A, they bore no resemblance to Zmpste24 2/2 mice. Unlike Zmpste24 2/2 mice, Lmna nPLAO/nPLAO mice maintained a normal or near-normal body weight, and they had no osteolytic lesions or bone fractures. In contrast to the Zmpste24 2/2 mice, Lmna nPLAO/nPLAO mice did develop a dilated cardiomyopathy. The most and Lmna nPLAO/nPLAO fibroblasts. We examined fibroblasts that had been immortalized by repeated passaging (D) and also low-passage number primary embryonic fibroblasts (E). In both cases, we observed no significant difference in nuclear deformation under uniaxial strain application, compared with Lmna +/+ cells. The extent of nuclear deformations was measured and is expressed as a ratio of nuclear strain to applied membrane strain (normalized nuclear strain). parsimonious interpretation of our findings is that the lipid anchor on prelamin A is central to disease phenotypes in Zmpste24 2/2 mice, whereas the extra 15 amino acid residues at the end of prelamin A are not. In addition, we conclude that non-farnesylated prelamin A leads to a distinct disease phenotype, dilated cardiomyopathy, which is not found in Zmpste24 2/2 mice. Clearly, non-farnesylated prelamin A is not functionally equivalent to mature lamin A.
The involvement of Lmna in cardiomyopathy is not without precedent. In humans, many LMNA missense mutations cause muscular dystrophy and/or dilated cardiomyopathy with conduction system disease (29) (30) (31) . Several of the missense mutations observed in humans have been introduced into mouse Lmna, and homozygous mice for those mutations manifest cardiomyopathy and premature death (26, 32) . The available data suggest that lamin A/C-related cardiomyopathy could be caused by increased nuclear fragility and changes in gene expression, in particular the MAPK pathway (33) . Interestingly, no one has yet found a case of cardiomyopathy due to a missense mutation involving the last 15 amino acids of prelamin A, nor has anyone identified a CaaX motif mutation leading to the production of non-farnesylated prelamin A.
The conclusion that non-farnesylated prelamin A leads to cardiomyopathy, but not progeria, is subject to several caveats. First, we would point out that Lmna nPLAO/nPLAO mice are incapable of producing lamin C. Thus, one could conceivably postulate that the cardiomyopathy is elicited by the inability to make that lamin isoform. However, this explanation seems unlikely, given the complete absence of cardiomyopathy or decreased survival in Lmna PLAO/PLAO mice (which also cannot make lamin C). It remains a formal possibility that cardiomyopathy is caused by non-farnesylated prelamin A, but only in the absence of lamin C. Second, it is important to note that prelamin A farnesylation was eliminated in Lmna nPLAO/nPLAO mice by introducing a cysteine-to-serine substitution in prelamin A's CaaX motif. That amino acid substitution is remarkably subtle, amounting to replacing a single sulfur atom with an oxygen atom. Nevertheless, one could propose that this amino acid substitution is solely responsible for the cardiomyopathy. Against that idea, however, is the absence of cardiomyopathy in 'non-farnesylated progerin mice' (12) , which share the identical cysteine-to-serine substitution in the CaaX motif.
The ideal scenario would be to create 'non-farnesylated prelamin A mice' without introducing any mutation into prelamin A's CaaX motif. Unfortunately, we are not aware of any strategy that would make this possible. In theory, one could achieve this goal by eliminating the expression of FTase, a genetic intervention that would lead to the accumulation of nonfarnesylated prelamin A (34). For such an approach to be practical, however, FTase deficiency could not elicit any of its own The absence of disease phenotypes in Lmna PLAO/PLAO mice implies that lamin C synthesis is dispensable in the laboratory mouse. In earlier studies, Fong et al. (38) found no disease phenotypes in mice synthesizing exclusively lamin C (Lmna LCO/LCO ), leading them to conclude that lamin A synthesis is dispensable. An absence of 'both' lamin A and lamin C causes muscular dystrophy and cardiomyopathy (39) . Thus, a key lesson from the Lmna PLAO/PLAO and Lmna LCO/LCO models is that lamin A alone, or lamin C alone, is capable of preventing disease. Also, when we state that each isoform is 'dispensable', we simply mean only that an absence of one isoform does not lead to obvious disease. In the future, it is conceivable that newer and more sensitive assays could uncover unique and important physiologic roles for each of the two protein isoforms. Dogma has held that prelamin A's hydrophobic lipid anchor is important for the targeting of the protein to the inner nuclear membrane (which is adjacent to the nuclear lamina). In part, this conclusion rested on the observation that prelamin A appears in the nucleoplasm of cultured fibroblasts, rather than at the nuclear rim, when protein farnesylation is inhibited (40) . Also, two groups reported that when a 'non-farnesylated prelamin A construct' was transfected into cells, the prelamin A did not reach the nuclear rim (5, 41) . A third study found that some non-farnesylated prelamin A reached the nuclear rim, but with delayed kinetics (42) . Recently, however, the conclusion that farnesylation is important for the nuclear envelope targeting of prelamin A has been challenged. Lamin C, which is never farnesylated, reaches the nuclear rim, even in the absence of lamin A, suggesting that farnesylation is not a requirement for nuclear rim localization of that nuclear lamin (38) . Lee et al. (34) generated keratinocyte-specific FTase knockout mice and showed that FTase-deficient keratinocytes accumulate substantial amounts of non-farnesylated prelamin A. Taking advantage of a new monoclonal antibody against mouse prelamin A, Lee et al. (34) showed that the nonfarnesylated prelamin A in FTase-deficient keratinocytes is located largely or exclusively at the nuclear rim, indistinguishable from the localization of mature lamin A in wild-type keratinocytes. Little if any non-farnesylated prelamin A was found in the nucleoplasm. In the current study, we observed consistent findings. As judged by immunofluorescence microscopy, virtually all of the non-farnesylated prelamin A in the heart and liver of Lmna nPLAO/nPLAO mice was located at the nuclear rim. Indeed, the distribution of non-farnesylated prelamin A in those tissues was identical to the distribution of mature lamin A in Lmna PLAO/PLAO tissues. Thus, prelamin A's farnesyl lipid anchor is not required for targeting to the nuclear rim. In Lmna nPLAO/nPLAO fibroblasts, non-farnesylated prelamin A was also found at the nuclear rim, although the amount was somewhat less than the amount of mature lamin A at the nuclear rim in wild-type fibroblasts.
Several years ago, Fong et al. (8, 38) showed that the disease phenotypes in Zmpste24 2/2 mice could be eliminated by reducing farnesyl-prelamin A production, either by introducing an Lmna knockout allele or an Lmna LCO allele (an allele yielding exclusively lamin C). Those findings supported the concept that farnesyl-prelamin A is toxic and provided the first suggestion that strategies to reduce prelamin A production could be therapeutically useful in progeria. The current studies with the Lmna PLAO allele further underscore the toxicity of farnesylprelamin A. Because the Lmna PLAO allele yields exclusively prelamin A, Zmpste24 2/2 mice harboring that allele synthesize increased amounts of farnesyl-prelamin A. Larger amounts of farnesyl-prelamin A clearly lead to more toxicity: the disease phenotypes in Zmpste24 2/2 Lmna PLAO/PLAO mice were far more severe than those in Zmpste24 2/2 Lmna PLAO/+ mice, which in turn were more severe than those in Zmpste24 2/2 Lmna +/+ mice. From the standpoint of therapy, the current study would suggest that an FTI has the potential to be a double-edged sword. On the one hand, our findings suggest that reducing protein farnesylation with an FTI might be useful, in that nonfarnesylated prelamin A appears to be devoid of the capacity to elicit progeria-like disease phenotypes. That conclusion is consistent with an earlier study showing that an FTI Figure 7 . Fibrosis within an LV papillary muscle from a male Lmna nPLAO/nPLAO mouse, as judged by a Gomori trichrome stain. This Lmna nPLAO/nPLAO mouse had severe LV dysfunction, as judged by echocardiography. Fibrotic tissue is stained green. No papillary muscle fibrosis was observed in an age-and sexmatched littermate Lmna +/+ mouse. Scale bars represent 100 mm.
ameliorates disease in Zmpste24 2/2 mice (43). On the other hand, our studies offer a darker possibility-that nonfarnesylated prelamin A carries its own distinctive toxicity, dilated cardiomyopathy. Thus, it is theoretically possible that any accumulation of non-farnesylated prelamin A, such as would occur with a long-term FTI therapy, could adversely affect the heart. Fortunately, we are not aware of any reports of cardiomyopathy with FTI therapy in humans, nor have we observed any evidence of cardiomyopathy when treating mice with an FTI, but any physician contemplating long-term FTI treatment for progeroid disorders should be attuned to this possibility.
MATERIALS AND METHODS

Generation of knock-in mice
To create a mutant Lmna allele yielding only non-farnesylated prelamin A (Lmna nPLAO ), we used a gene-targeting vector similar to one used to create a mutant allele yielding exclusively progerin (Lmna HG ) (18) . Introns 10 and 11 of Lmna were deleted by site-directed mutagenesis (QuikChange; Stratagene, La Jolla, CA, USA). The oligonucleotide 5 ′ -GATG GAGAAGAGCTCCTCCATCACCACCGTGGTTCCCACTG CAGCGGCTCGGGGGACCCC-3 ′ and its reverse complement were used to delete intron 10; oligonucleotide 5 ′ -CT CCTGGGCAACTCCAGTCCCCGGAGCCAGAGCTCCCA GAACTGCAGCATCATGTAATCT-3 ′ and its reverse complement were used to delete intron 11. Also, a point mutation was introduced into exon 12 that changes the cysteine of prelamin A's CaaX motif to a serine (i.e. 2CSIM to 2SSIM). The mutation was introduced into the 5 ′ arm of the vector by site-directed mutagenesis with the QuikChange kit (Stratagene) and oligonucleotide 5
′ -CAGAGCTCCCAGAA CTCGAGCATCATGTAATCT-3 ′ (and the complementary primer). To create a mutant Lmna allele yielding only wildtype prelamin A (Lmna PLAO ), the same gene-targeting vector was used, except that the CaaX motif was not changed. and Lmna
PLAO/PLAO
Zmpste24
2/2 mice. Genotyping of mice was performed by PCR using DNA from tail biopsies (18) . All mice were fed a chow diet and housed in a virus-free barrier facility with a 12 h light-dark cycle. All mouse experiments were approved by UCLA's Animal Research Committee.
Western blots and metabolic labeling
Primary mouse embryonic fibroblasts were prepared from embryonic day 13.5 embryos (6). To block protein farnesylation, we added a highly selective FTI, ABT-100 (5 mM), to the cell culture medium.
Urea-soluble extracts were prepared as described previously (45) . Extracts were size-fractionated on 4 -12% gradient polyacrylamide Bis -Tris gels (Invitrogen), and the separated proteins transferred to nitrocellulose membranes for western blotting. Antibody dilutions were 1:200 for anti-lamin A/C goat IgG (sc-6215, Santa Cruz Biotechnology), 1:1000 for anti-actin goat IgG (sc-1616, Santa Cruz Biotechnology) and 1:5000 for IRDye 800 anti-goat IgG (Rockland Immunochemicals). The IR-coupled antibodies were detected with an Odyssey infrared imaging scanner and quantified according to the manufacturer's instructions. To assess protein farnesylation, fibroblasts were incubated for 48 h with an analog of farnesol, AG (50 mM in DMSO) (24) . AG is incorporated into AGPP and used as a substrate by protein farnesyltransferase. The incorporation of AG into CaaX proteins such as prelamin A can be detected by western blotting with an AG-specific mouse monoclonal antibody (1:5000) (24) and an IRDye 680 anti-mouse IgG (1:2500) (Li-Cor).
Analysis of nuclear shape in fibroblasts
To assess nuclear shape abnormalities, early-passage mouse embryonic fibroblasts were grown on coverslips and then fixed and permeabilized (8) . Cells were incubated with antibodies against lamin A (1:50, sc-20680, Santa Cruz Biotechnology) and prelamin A (1:50, clone 3C8) for 2 h. After washing, cells were incubated with Alexa Fluor 568-conjugated antirabbit antibody (1:500, Jackson ImmunoResearch Laboratories), Alexa Fluor 488-conjugated anti-rat antibody (1:500, Invitrogen) and DAPI to visualize DNA. Images were obtained on an Axiovert 200 MOT microscope (Zeiss) or on a Leica SP2 1P-FCS confocal microscope and nuclear shape was assessed ( 1000 cells/genotype).
Analysis of nuclear stiffness in fibroblasts
Nuclear strain studies were performed as described previously (46) , with the following modification. Cells were subjected to 20% uniaxial strain rather than biaxial strain. Membrane and nuclear deformations were computed based on bright-field and fluorescent images acquired before, during and after strain application. Normalized nuclear strain was defined as the ratio of nuclear strain to membrane strain to compensate for small variations in applied membrane strain. Cells that were damaged during or after strain application were excluded from the analysis.
Immunohistochemistry
To assess the location of lamin A and prelamin A in tissues, 6-10-mm-thick frozen sections were prepared and placed on glass slides. The sections were fixed with cold (2208C) methanol for 10 min, rinsed with acetone, permeabilized with 0.1% Tween in PBS, and then incubated in a PBS blocking buffer containing 0.1% Tween and 5% donkey serum for 1 h at room temperature. The sections were incubated with primary antibodies in blocking buffer overnight at a dilution of 1:50 for a rabbit anti-lamin A antibody (Santa Cruz Biotechnology), 1:50 for a rat anti-prelamin A monoclonal antibody (3C8) and 1:50 for a rat anti-prelamin A antibody (7G11). Monoclonal antibodies 7G11 and 3C8 were derived from rats immunized with a C-terminal peptide of mouse prelamin A (34) . After washing the sections, they were incubated for 1 h at room temperature with fluorescently labeled secondary antibodies (1:200 Alexa488-labeled anti-rat IgG; 1:200 Alexa568-labeled anti-rabbit IgG). The sections were then washed, post-fixed with 4% paraformaldehyde in PBS and stained with DAPI to visualize DNA. Images were obtained with an Axiovert 200 MOT microscope equipped with an Apotome and processed with AxoVision 4.2 software (Zeiss, Germany).
Analysis of mouse phenotypes
Body weights were measured weekly for 20 weeks and then every other week; numbers of surviving mice were recorded weekly. To assess osteolytic lesions and rib fractures, the thoracic cages of Zmpste24 2/2 , Lmna +/+ , Lmna PLAO/PLAO and Lmna nPLAO/nPLAO mice were imaged by X-ray microtomography (mCT) with the Skyscan 1172 system (Skyscan). 
Histology
To assess fibrosis, Lmna +/+ and Lmna nPLAO/nPLAO mice were perfused with 4% paraformaldehyde, and the hearts were removed and post-fixed in 3% formalin. Fixed tissues were embedded in paraffin, sectioned and stained with Gomori trichrome and hematoxylin.
Quantitative reverse transcribed -PCR
Total RNA was prepared from mouse hearts with the RNeasy kit (Qiagen). RNA was treated with DNase I (Ambion) and reverse transcribed (RT) with a mixture of random primers, oligo(dT) and Superscript III (Invitrogen). Primers 5 ′ -CGCA TCAAGGAGCTCACC-3 ′ and 5 ′ -CCTGCAGCCGCATTA AGT-3 ′ were used to amplify the mouse Myh6 cDNA, and primers 5
′ -GGAAGACAGGAAGAACCTACTGC-3 ′ and 5 ′ -AA CTTGGACAGGTTGGTGTTG-3 ′ were used to amplify mouse Myh7 cDNA. Expression was normalized to GAPDH (amplified with the primers 5 ′ -GCACAGTCAAGGCCGAGAAT-3 ′ and 5
′ -GCCTTCTCCATGGTGGTGAA-3 ′ ). PCRs were performed in triplicate on a 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). Gene-expression levels were calculated with the comparative cycle threshold (C T ) method.
Statistical analyses
Differences in misshapen nuclei were analyzed using the x 2 test. Variations in nuclear strain assays were analyzed by one-way ANOVA with Tukey's multiple comparison post-test. The number of surviving male and female mice was recorded weekly. Differences were assessed by the log-rank (Mantel -Cox) and the Gehan -Breslow -Wilcoxon tests. Body weight curves were compared with repeatedmeasures ANOVA. Echocardiographic data and gene-expression data were analyzed with the Student's t-test.
